购物车
  • 全部删除
  • TargetMol
    您的购物车当前为空

GM-CSF/CSF2 Protein, Human, Recombinant, Biotinylated

产品编号 TMPY-05236
GM-CSF/CSF2 Protein, Human, Recombinant, Biotinylated is expressed in HEK293 mammalian cells. The predicted molecular weight is 14.5 kDa and the accession number is P04141.
规格价格库存数量
20 μg
¥ 2,440
5日内发货
100 μg
¥ 5,810
5日内发货
大包装 & 定制
加入购物车
TargetMol 的所有产品仅用作科学研究或药证申报,不能被用于人体,我们不向个人提供产品和服务。请您遵守承诺用途,不得违反法律法规规定用于任何其他用途。
实验操作小课堂
常见问题解答
重组蛋白有吗?
您需要什么种属的蛋白呢,对表达系统和标签有要求吗,用于什么实验?
为什么重组蛋白的体积和质量与预期不符?
蛋白冻干粉由蛋白原液冻干而来,冻干粉质量不等同于蛋白质量。由于冻⼲产品的体积大⼩受多种因素影响,包括冻⼲前缓冲液的组分、盐离⼦浓度以及产品本身的浓度等。冻⼲粉可能看上去很多,也可能肉眼不易观察到,这些都是正常现象,请您放心使用。在收到产品后,照常复溶、使用或分装储存即可。
为什么某些重组蛋白溶液中还需要添加载体蛋白?
载体蛋白通常被用于提高蛋白的稳定性,防止蛋白在冷冻或解冻过程中粘附在管壁上。塑料管对蛋白有一定的吸附能力,这可能导致蛋白和管壁之间难以分离,导致溶液中蛋白的实际浓度下降,从而影响其活性。为减少这种损失,在长期保存重组蛋白 产品之前,建议添加常用的载体蛋白溶液,例如0.1% BSA(牛血清白蛋白)、5% HSA(人血清白蛋白)、10% FBS(胎牛血清)或 5% 海藻糖等。如果重组蛋白的浓度较低,强烈建议添加适量的载体蛋白。
如何将冻干的重组蛋白配置为储备液?
在打开盖⼦之前,先使用 10000-12000 rpm 的转速进行离心,20-30 秒,将附着在管盖或管壁上的冻⼲粉收集到管底,以避免损失。大多数蛋白可通过加入无菌蒸馏水来重新溶解。如果需要除水以外的其他稀释剂,产品 COA 中会对其进行说明。一般储备液浓度建议不要低于 100 μg/mL,分装储存避免反复冻融。
蛋白能保证活性吗?
我们有现货的产品,有活性数据的话会展示在官网生物活性那栏,没有数据的也不代表就一定没有活性,是我们还没有建立活性检测方法,没有进行测试,但是我们的蛋白都是优先按照有活性的方法去表达纯化的。
查看更多

产品信息

生物活性
Activity testing is in progress. It is theoretically active, but we cannot guarantee it. If you require protein activity, we recommend choosing the eukaryotic expression version first.
产品描述
GM-CSF/CSF2 Protein, Human, Recombinant, Biotinylated is expressed in HEK293 mammalian cells. The predicted molecular weight is 14.5 kDa and the accession number is P04141.
种属
Human
表达系统
HEK293 Cells
标签Tag Free
蛋白编号P04141
别名
集落刺激因子,GM-CSF,GMCSF,CSF2,colony stimulating factor 2 (granulocyte-macrophage)
蛋白构建
A DNA sequence encoding the human CSF2 (NP_000749.2) (Met1-Glu144) was expressed. The purified protein was biotinylated in vitro. Predicted N terminal: Ala 18
蛋白纯度
> 85 % as determined by SDS-PAGE.
分子量14.5 kDa (predicted)
内毒素< 1.0 EU/μg of the protein as determined by the LAL method.
缓冲液Lyophilized from a solution filtered through a 0.22 μm filter, containing Sterile PBS. Typically, a mixture containing 5% to 8% trehalose, mannitol, and 0.01% Tween 80 is incorporated as a protective agent before lyophilization.
复溶方法
A Certificate of Analysis (CoA) containing reconstitution instructions is included with the products. Please refer to the CoA for detailed information.
存储
It is recommended to store recombinant proteins at -20°C to -80°C for future use. Lyophilized powders can be stably stored for over 12 months, while liquid products can be stored for 6-12 months at -80°C. For reconstituted protein solutions, the solution can be stored at -20°C to -80°C for at least 3 months. Please avoid multiple freeze-thaw cycles and store products in aliquots.
运输方式In general, Lyophilized powders are shipping with blue ice.
研究背景
Granulocyte-macrophage colony-stimulating factor (GM-CSF) is one of an array of cytokines with pivotal roles in embryo implantation and subsequent development. Several cell lineages in the reproductive tract and gestational tissues synthesise GM-CSF under direction by ovarian steroid hormones and signalling agents originating in male seminal fluid and the conceptus. The pre-implantation embryo, invading placental trophoblast cells and the abundant populations of leukocytes controlling maternal immune tolerance are all subject to GM-CSF regulation. GM-CSF stimulates the differentiation of hematopoietic progenitors to monocytes and neutrophils, and reduces the risk for febrile neutropenia in cancer patients. GM-CSF also has been shown to induce the differentiation of myeloid dendritic cells (DCs) that promote the development of T-helper type 1 (cellular) immune responses in cognate T cells. The active form of the protein is found extracellularly as a homodimer, and the encoding gene is localized to a related gene cluster at chromosome region 5q31 which is known to be associated with 5q-syndrome and acute myelogenous leukemia. As a part of the immune/inflammatory cascade, GM-CSF promotes Th1 biased immune response, angiogenesis, allergic inflammation, and the development of autoimmunity, and thus worthy of consideration for therapeutic target. GM-CSF has been utilized in the clinical management of multiple disease processes. Most recently, GM-CSF has been incorporated into the treatment of malignancies as a sole therapy, as well as a vaccine adjuvant. While the benefits of GM-CSF in this arena have been promising, recent reports have suggested the potential for GM-CSF to induce immune suppression and, thus, negatively impact outcomes in the management of cancer patients. GM-CSF deficiency in pregnancy adversely impacts fetal and placental development, as well as progeny viability and growth after birth, highlighting this cytokine as a central maternal determinant of pregnancy outcome with clinical relevance in human fertility.Cancer ImmunotherapyImmune CheckpointImmunotherapyTargeted Therapy

参考文献

SCI 文献

计算器

  • 复溶 计算器
  • 重组蛋白稀释 计算器
  • 比活力 计算器

技术支持

请阅读 重组蛋白用户指南 了解更多具体信息.

关键词

失败
网络或系统异常,请稍后再试